Evaluation of Gender-Affirming Treatments on Pulmonary Function in Transgender and Gender Diverse Patients
Evaluating the Impact of Gender-Affirming Treatments on Pulmonary Function in Transgender and Gender Diverse (TGD) Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kayla Quinn, MS
- Phone Number: 800-752-1606
- Email: quinn.kayla2@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Rochester
-
Contact:
- Kayla L Macdonald
- Phone Number: (507)538-0595
- Email: macdonald.kayla@mayo.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects speaking any language will be offered participation.
- Subjects capable of providing informed consent to the study. For those subjects younger than 18 years old who agree to participate in the study, informed consent will be obtained from patient's parents/guardian.
- Subjects capable of performing pulmonary function test (PFT) maneuvers, as per pulmonary function test laboratory protocol.
- Patients will be enrolled through the Mayo Clinic Rochester Transgender and Intersex
- Specialty Care Clinic (TISCC), once patient has decided to undergo hormonal gender-affirming therapies (pubertal blockers, and masculinizing or feminizing hormone therapies).
Exclusion Criteria:
- Subjects unable to provide consent, or subjects who do not agree to discuss the study with their parents/guardians.
The presence of contraindications for pulmonary function testing including (these will be reviewed at the time of recruitment and prior to each spirometry associated with the study):
- Recent surgical procedures (<3 months) that could be affected by lung function testing, including the following categories: Abdominal surgery, Eye surgery, Thoracic surgery, Ear surgery, Brain surgery, Vascular surgery.
- The presence of previously known respiratory disorders including pulmonary embolism (<6 months), pleural effusion, pneumothorax, hemoptysis.
- Recent myocardial infarction (<1 month), new cardiac arrythmia (<3 months), recent cardiac pacemaker implantation (<3 months).
- Heart failure symptoms, significant shortness of breath, tachycardia, or angina
- The presence of chronic pulmonary diseases that maybe associated with changes in pulmonary function overtime such as asthma, chronic obstructive pulmonary disease, or interstitial lung diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pulmonary Function in Transgender and Gender Diverse Patients
Transgender and gender diverse (TGD) patients undergoing masculinizing or feminizing hormone therapies will have breathing tests to evaluate their lung function
|
Pulmonary function test to measure lung function
Pulmonary function test to measure lung volume
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in lung volume (Total Lung Capacity, Vital Capacity, Functional Residual Capacity, Residual Volume)
Time Frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
The longitudinal changes in lung volumes after both masculinizing and feminizing hormone therapy in transgender and gender diverse (TGD) patients.
|
Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
|
Change in forced expiratory volume
Time Frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
Measured by spirometry to determine the volume of air that can be exhaled in 1 second with a forced breath
|
Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
|
Change in forced vital capacity
Time Frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
Measured by spirometry to determine the maximal amount of air that can be forcibly exhaled from the lungs after a full inhale, reported as liters (L)
|
Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
|
Change in peak expiratory flow
Time Frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
Measured by a peak flow meter is the maximum forced expiratory flow, reported in liter per minute (L/min)
|
Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
|
Change in maximal mid-expiratory flow rate
Time Frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
Measured by spirometry to determine the rate of airflow where half of the forced vital capacity is exhaled
|
Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time of "gender adjustment" of PFT's normative values
Time Frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
The time of "gender adjustment" of PFT's normative values (PFTs results correlate most closely with patient's gender than with their sex-assigned at birth) in response to gender-affirming hormone therapy in transgender and gender diverse (TGD) patients.
|
Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gustavo Cortes Puentes, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22-007173
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.